Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy NJ Curtin et al, Nature Rev Clin Oncology, October 3, 2019

Main|Search|PHGKB




Last Posted: Oct 04, 2019

---

• After a Breast Cancer Diagnosis, Men May Be More Likely to Die than Women
  NCI, October 2, 2019
• Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
  NJ Curtin et al, Nature Rev Clin Oncology, October 3, 2019
• BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
  Oh Mok et al. Journal of the National Cancer Institute 2018 110(11) 1178-1189
• Mathew Knowles reveals he is battling breast cancer: 'We need men to speak out'
  H FitzPatrick et al, ABC Good Morning America, October 2, 2019
• [Views of Icelandic women towards genetic counseling - and testing of BRCA2 mutations].
  Jonsdottir Thordis et al. Laeknabladid 104(6) 289-296
• Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
  Johns Dana et al. Journal of women's health (2002) 2017 26(6) 702-706
• Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers.
  Nurudeen Suliat et al. American journal of surgery 2017 Oct 214(4) 687-694
• Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?
  Young Alison Luk et al. Journal of genetic counseling 2019 Sep
• Cancer: more genetic BRCA testing for men.
  Marabelli Monica et al. Nature 2019 Sep 573(7774) 346
• Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
  Manchanda R et al. BJOG : an international journal of obstetrics and gynaecology 2019 Sep

more